MedTrace Logo

The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

NCT06507436 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2025-11-18

No results posted yet for this study

Summary

This study includes Part A and Part B. Part A is a dose-finding study for subjects with chronic liver disease-related thrombocytopenia scheduled for elective surgery. Part B is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy and safety of Herombopag compared to placebo in patients with chronic liver disease-related thrombocytopenia undergoing elective invasive surgery.

Conditions

  • Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

Interventions

DRUG

Herombopag tablets

Herombopag tablets; dose 1 or dose 2, for 5 days

DRUG

Herombopag placebo tablets

Herombopag placebo tablets; dose 1 or dose 2, for 5 days

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-31
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06507436 on ClinicalTrials.gov